122 related articles for article (PubMed ID: 38588876)
1. Inhibition of PRMT5-mediated regulation of DKK1 sensitizes colorectal cancer cells to chemotherapy.
Abumustafa W; Castven D; Becker D; Salih SS; Manzoor S; Zamer BA; Talaat I; Hamad M; Marquardt JU; Muhammad JS
Cell Signal; 2024 Jul; 119():111166. PubMed ID: 38588876
[TBL] [Abstract][Full Text] [Related]
2. Protein arginine methyltransferase 5 (PRMT5) activates WNT/β-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3.
Shailesh H; Siveen KS; Sif S
J Cell Mol Med; 2021 Feb; 25(3):1583-1600. PubMed ID: 33462997
[TBL] [Abstract][Full Text] [Related]
3. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
4. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
[TBL] [Abstract][Full Text] [Related]
5. PRMT5 promotes colorectal cancer growth by interaction with MCM7.
Li X; Wang X; Zhao J; Wang J; Wu J
J Cell Mol Med; 2021 Apr; 25(7):3537-3547. PubMed ID: 33675123
[TBL] [Abstract][Full Text] [Related]
6. Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation.
Ge S; Zhang Q; Chen Y; Tian Y; Yang R; Chen X; Li F; Zhang B
Toxicol Appl Pharmacol; 2021 Mar; 415():115450. PubMed ID: 33577917
[TBL] [Abstract][Full Text] [Related]
7. PRMT5 regulates colorectal cancer cell growth and EMT via EGFR/Akt/GSK3β signaling cascades.
Yan Y; Zhao P; Wang Z; Liu Z; Wang Z; Zhang J; Ding Y; Hua X; Yu L
Aging (Albany NY); 2021 Jan; 13(3):4468-4481. PubMed ID: 33495409
[TBL] [Abstract][Full Text] [Related]
8. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
9. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
10. KRAS Mutation-Responsive miR-139-5p inhibits Colorectal Cancer Progression and is repressed by Wnt Signaling.
Du F; Cao T; Xie H; Li T; Sun L; Liu H; Guo H; Wang X; Liu Q; Kim T; Franklin JL; Graves-Deal R; Han W; Tian Z; Ge M; Nie Y; Fan D; Coffey RJ; Lu Y; Zhao X
Theranostics; 2020; 10(16):7335-7350. PubMed ID: 32641995
[No Abstract] [Full Text] [Related]
11. Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies.
Abumustafa W; Zamer BA; Khalil BA; Hamad M; Maghazachi AA; Muhammad JS
Biomed Pharmacother; 2022 Jan; 145():112368. PubMed ID: 34794114
[TBL] [Abstract][Full Text] [Related]
12. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
13. PRMT5-mediated methylation of YBX1 regulates NF-κB activity in colorectal cancer.
Hartley AV; Wang B; Mundade R; Jiang G; Sun M; Wei H; Sun S; Liu Y; Lu T
Sci Rep; 2020 Sep; 10(1):15934. PubMed ID: 32985589
[TBL] [Abstract][Full Text] [Related]
14. NAA40 contributes to colorectal cancer growth by controlling PRMT5 expression.
Demetriadou C; Pavlou D; Mpekris F; Achilleos C; Stylianopoulos T; Zaravinos A; Papageorgis P; Kirmizis A
Cell Death Dis; 2019 Mar; 10(3):236. PubMed ID: 30858358
[TBL] [Abstract][Full Text] [Related]
15. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
[TBL] [Abstract][Full Text] [Related]
16. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
[TBL] [Abstract][Full Text] [Related]
17. Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer.
Aguilera Ó; González-Sancho JM; Zazo S; Rincón R; Fernández AF; Tapia O; Canals F; Morte B; Calvanese V; Orgaz JL; Niell N; Aguilar S; Freije JM; Graña O; Pisano DG; Borrero A; Martínez-Useros J; Jiménez B; Fraga MF; García-Foncillas J; López-Otín C; Lafarga M; Rojo F; Muñoz A
Oncotarget; 2015 Mar; 6(8):5903-17. PubMed ID: 25788273
[TBL] [Abstract][Full Text] [Related]
18. Protein Arginine Methyltransferase 5 as a Therapeutic Target for
Shifteh D; Sapir T; Pahmer M; Haimowitz A; Goel S; Maitra R
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32731506
[TBL] [Abstract][Full Text] [Related]
19. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
Wang Z; Kong J; Wu Y; Zhang J; Wang T; Li N; Fan J; Wang H; Zhang J; Ling R
Breast Cancer Res Treat; 2018 Apr; 168(2):531-542. PubMed ID: 29185119
[TBL] [Abstract][Full Text] [Related]
20. Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers.
Prabhu L; Wei H; Chen L; Demir Ö; Sandusky G; Sun E; Wang J; Mo J; Zeng L; Fishel M; Safa A; Amaro R; Korc M; Zhang ZY; Lu T
Oncotarget; 2017 Jun; 8(25):39963-39977. PubMed ID: 28591716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
